Slower heart rates for healthy hearts: time to redefine tachycardia?

Circ Arrhythm Electrophysiol. 2008 Dec;1(5):321-3. doi: 10.1161/CIRCEP.108.835264.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Atenolol / therapeutic use
  • Atrial Fibrillation / etiology
  • Atrial Fibrillation / physiopathology*
  • Atrial Fibrillation / prevention & control
  • Electrocardiography
  • Heart Rate* / drug effects
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy
  • Hypertension / physiopathology*
  • Hypertrophy, Left Ventricular / etiology
  • Hypertrophy, Left Ventricular / physiopathology*
  • Hypertrophy, Left Ventricular / prevention & control
  • Incidence
  • Losartan / therapeutic use
  • Reference Values
  • Risk Assessment
  • Risk Factors
  • Tachycardia / physiopathology*
  • Time Factors
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Atenolol
  • Losartan